BCRX
BioCryst Pharmaceuticals Inc
Price:  
5.87 
USD
Volume:  
3,694,642.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

BCRX EV/EBITDA

-297.0%
Upside

As of 2024-02-28, the EV/EBITDA ratio of BioCryst Pharmaceuticals Inc (BCRX) is -17.82. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BCRX's latest enterprise value is 1,884.53 mil USD. BCRX's TTM EBITDA according to its financial statements is -105.74 mil USD. Dividing these 2 quantities gives us the above BCRX EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 12.3x - 19.3x 13.8x
Forward P/E multiples 16.7x - 21.6x 18.1x
Fair Price (11.97) - (13.31) (11.57)
Upside -304.0% - -326.7% -297.0%
5.87 USD
Stock Price
(11.57) USD
Fair Price

BCRX EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-02-27 -17.82
2024-02-26 -17.67
2024-02-23 -17.51
2024-02-22 -17.73
2024-02-21 -17.40
2024-02-20 -17.73
2024-02-16 -17.92
2024-02-15 -17.38
2024-02-14 -17.24
2024-02-13 -16.76
2024-02-12 -17.98
2024-02-09 -17.78
2024-02-08 -16.76
2024-02-07 -16.72
2024-02-06 -17.13
2024-02-05 -16.41
2024-02-02 -16.29
2024-02-01 -16.68
2024-01-31 -16.72
2024-01-30 -17.11
2024-01-29 -17.43
2024-01-26 -16.99
2024-01-25 -17.01
2024-01-24 -16.91
2024-01-23 -17.11
2024-01-22 -17.34
2024-01-19 -17.43
2024-01-18 -17.61
2024-01-17 -18.00
2024-01-16 -18.25
2024-01-12 -18.75
2024-01-11 -18.98
2024-01-10 -19.78
2024-01-09 -20.86
2024-01-08 -21.27
2024-01-05 -18.25
2024-01-04 -18.97
2024-01-03 -18.07
2024-01-02 -18.21
2023-12-29 -18.05
2023-12-28 -18.25
2023-12-27 -18.44
2023-12-26 -18.23
2023-12-22 -17.96
2023-12-21 -17.61
2023-12-20 -17.38
2023-12-19 -18.17
2023-12-18 -18.21
2023-12-15 -18.44
2023-12-14 -18.91